AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 23093468 — intervention group
Group type: COMPARATOR
Intervention: Dangling procedure starting at day 7, with wrapping and dangling performed for 5 minutes three times a day, increasing to 60 minutes by day 5.
Number of subjects: 31
Study 21330894 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fidelity simulation
Number of subjects: 49
Study 21330894 — intervention group
Group type: COMPARATOR
Intervention: Static simulation
Number of subjects: 49
Study 19070758 — intervention group
Group type: EXPERIMENTAL
Intervention: Tranexamic acid (20 mg/kg)
Number of subjects: 73
Study 19070758 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline)
Number of subjects: 73
Study 19070758 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 73
Study 16360143 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lead level (BLL) > 2.5 microg/dL
Number of subjects: 147
Study 16360143 — intervention group
Group type: COMPARATOR
Intervention: Blood lead level (BLL) ≤ 2.5 microg/dL
Number of subjects: 147
Study 16360143 — intervention group
Group type: EXPERIMENTAL
Intervention: Mean blood lead level in infertile women
Number of subjects: 147
Study 16360143 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood lead level as a predictor
Number of subjects: 147
Study 15466632 — intervention group
Group type: EXPERIMENTAL
Intervention: Theophylline
Number of subjects: 0
Study 11571241 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior CABG
Number of subjects: 5410
Study 11571241 — intervention group
Group type: COMPARATOR
Intervention: Patients without prior CABG
Number of subjects: 5410
Study 9130194 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual abuse prevention program (2-hour curriculum)
Number of subjects: 431
Study 9130194 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 431
Study 8023802 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported dietary habits and tobacco exposure assessment
Number of subjects: 203
Study 8023802 — intervention group
Group type: EXPERIMENTAL
Intervention: Use of supplements that did not contain carotene
Number of subjects: 203
Study 2662802 — intervention group
Group type: EXPERIMENTAL
Intervention: 24 hours' recumbency
Number of subjects: 102
Study 2662802 — intervention group
Group type: COMPARATOR
Intervention: 4 hours' recumbency
Number of subjects: 102
Study 1181938 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral modification approach
Number of subjects: 0
Study 31860160 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal tDCS at 2.0-mA
Number of subjects: 29
Study 31860160 — intervention group
Group type: EXPERIMENTAL
Intervention: Cathodal tDCS at 2.0-mA
Number of subjects: 29
Study 31860160 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 29
Study 31289097 — intervention group
Group type: EXPERIMENTAL
Intervention: Counterclockwise intervention (1-week retreat, reliving younger selves in a retrofitted environment)
Number of subjects: 90
Study 31289097 — intervention group
Group type: COMPARATOR
Intervention: Active control group (same activities, no time manipulation)
Number of subjects: 90
Study 31289097 — intervention group
Group type: COMPARATOR
Intervention: No-treatment group
Number of subjects: 90
Study 28533151 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen deprivation therapy (ADT) with salvage radiation therapy (SRT)
Number of subjects: 4200
Study 28533151 — intervention group
Group type: EXPERIMENTAL
Intervention: ADT use predictors: presurgery PSA >20 ng/ml (AOR = 1.34, P = 0.002; 36.7% vs. 29.6%), positive margins (AOR = 1.29, P = 0.001; 34.9% vs. 27.8%), Gleason scores (Gleason 3+4 AOR = 1.53; 21.3%, 4+3 AOR = 2.40; 32.0%, 8 to 10 AOR = 4.49; 49.2% vs. 2 to 6; P≤0.005 for all; 13.2%), pathologic T stages (T3a AOR = 1.46; 30.9%, T3b AOR = 2.50; 47.6%, T4 AOR = 4.14; 60.9% vs. T2; P<0.001 for all; 19.1%).
Number of subjects: 4200
Study 28533151 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting SRT 12 to 23.9 months after RP
Number of subjects: 4200
Study 28533151 — intervention group
Group type: EXPERIMENTAL
Intervention: Starting SRT ≥24 months after RP
Number of subjects: 4200
Study 25936452 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS‐FNA with a stylet (S+)
Number of subjects: 107
Study 25936452 — intervention group
Group type: COMPARATOR
Intervention: EUS‐FNA without a stylet (S‐)
Number of subjects: 107
Study 24130354 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 to 2 portions of fruits and vegetables (F&Vs) per day
Number of subjects: 89
Study 24130354 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 portions of fruits and vegetables (F&Vs) per day
Number of subjects: 89
Study 24130354 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 portions of fruits and vegetables (F&Vs) per day
Number of subjects: 89
Study 24130354 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (1-2, 4, 7 portions of F&Vs)
Number of subjects: 89
Study 24130354 — intervention group
Group type: COMPARATOR
Intervention: Control (washout diet of 1-2 portions of F&Vs per day)
Number of subjects: 89
Study 21273210 — intervention group
Group type: EXPERIMENTAL
Intervention: Unweighted summed score
Number of subjects: 1101
Study 21273210 — intervention group
Group type: EXPERIMENTAL
Intervention: Weighted summed score
Number of subjects: 1101
Study 18937325 — intervention group
Group type: EXPERIMENTAL
Intervention: DTP vaccine (three doses administered)
Number of subjects: 56
Study 18937325 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vaccination)
Number of subjects: 56
Study 17707594 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief Motivational Interview (BMI)
Number of subjects: 225
Study 17707594 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-delivered intervention (CDI)
Number of subjects: 225
Study 17707594 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 225
Study 17707594 — intervention group
Group type: COMPARATOR
Intervention: Booster condition
Number of subjects: 225
Study 15483745 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with coronary artery disease
Number of subjects: 250
Study 15483745 — intervention group
Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 250
Study 15483745 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients and Control subjects
Number of subjects: 250
Study 11510750 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilnidipine
Number of subjects: 20
Study 11510750 — intervention group
Group type: COMPARATOR
Intervention: Benazepril
Number of subjects: 20
Study 10193254 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 1 ppm
Number of subjects: 12
Study 10193254 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 10 ppm
Number of subjects: 12
Study 10193254 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO) at 20 ppm
Number of subjects: 12
Study 10193254 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled nitric oxide (iNO)
Number of subjects: 12
Study 7921336 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol consumption
Number of subjects: 0
Study 7921336 — intervention group
Group type: COMPARATOR
Intervention: Placebo consumption
Number of subjects: 0
Study 3396485 — intervention group
Group type: COMPARATOR
Intervention: Short course prophylaxis (2g cefotaxime IV at anaesthesia)
Number of subjects: 293
Study 3396485 — intervention group
Group type: EXPERIMENTAL
Intervention: Long course prophylaxis (2g cefotaxime at anaesthesia plus 7 doses of 1g 12‐hourly)
Number of subjects: 293
Study 3396485 — intervention group
Group type: COMPARATOR
Intervention: Both treatments (short and long course)
Number of subjects: 293
Study 31831886 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin genetic risk score (GRS)
Number of subjects: 3860
Study 31831886 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin genetic risk score (GRS) among current smokers
Number of subjects: 3860
Study 31831886 — intervention group
Group type: EXPERIMENTAL
Intervention: Leptin genetic risk score (GRS) and smoking interaction
Number of subjects: 3860
Study 29119704 — intervention group
Group type: EXPERIMENTAL
Intervention: RP5063 (10 mg fasting, 15 mg fed/fasting)
Number of subjects: 0
Study 29119704 — intervention group
Group type: EXPERIMENTAL
Intervention: RP5063 (10, 20, 50, and 100 mg fed)
Number of subjects: 0
Study 29119704 — intervention group
Group type: EXPERIMENTAL
Intervention: RP5063 (single-dose study)
Number of subjects: 0
Study 27225353 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity physical activity (PA)
Number of subjects: 1635
Study 27225353 — intervention group
Group type: COMPARATOR
Intervention: Health education (HE)
Number of subjects: 1635
Study 25687353 — intervention group
Group type: EXPERIMENTAL
Intervention: Alirocumab 75 mg every 2 weeks
Number of subjects: 720
Study 25687353 — intervention group
Group type: COMPARATOR
Intervention: Ezetimibe 10 mg daily
Number of subjects: 720
Study 23305463 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet intervention 'Mastery over Dementia', consisting of an 8-session internet course with a booster session over a maximum period of 6 months, guided by a psychologist.
Number of subjects: 0
Study 23305463 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention (comparison condition).
Number of subjects: 0
Study 20642207 — intervention group
Group type: EXPERIMENTAL
Intervention: FAHF‐2 (2.2 g, 3 times a day for 7 days)
Number of subjects: 19
Study 20642207 — intervention group
Group type: EXPERIMENTAL
Intervention: FAHF‐2 (3.3 g, 3 times a day for 7 days)
Number of subjects: 19
Study 20642207 — intervention group
Group type: EXPERIMENTAL
Intervention: FAHF‐2 (6.6 g, 3 times a day for 7 days)
Number of subjects: 19
Study 20642207 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 times a day for 7 days)
Number of subjects: 19
Study 20642207 — intervention group
Group type: EXPERIMENTAL
Intervention: In vitro studies with FAHF‐2
Number of subjects: 19
Study 18622266 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteroids
Number of subjects: 0
Study 18622266 — intervention group
Group type: EXPERIMENTAL
Intervention: CRHR1 SNPs
Number of subjects: 0
Study 16306470 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg/day
Number of subjects: 152
Study 16306470 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 152
Study 12682474 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress doses of hydrocortisone (100 mg before induction of anesthesia, then 10 mg/hr for 24 hrs, 5 mg/hr for 24 hrs, 3 x 20 mg/day, and 3 x 10 mg/day)
Number of subjects: 91
Study 12682474 — intervention group
Group type: EXPERIMENTAL
Intervention: Stress doses of hydrocortisone
Number of subjects: 91
Study 12682474 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 91
Study 10869915 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane (8% in 50% nitrous oxide and oxygen)
Number of subjects: 78
Study 10869915 — intervention group
Group type: COMPARATOR
Intervention: Halothane (4% in 50% nitrous oxide and oxygen)
Number of subjects: 78
Study 9184782 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (15 mg/day)
Number of subjects: 24
Study 9184782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 8197889 — intervention group
Group type: EXPERIMENTAL
Intervention: Scheduled smoking procedure
Number of subjects: 34
Study 8197889 — intervention group
Group type: COMPARATOR
Intervention: Minimal contact self-help treatment control
Number of subjects: 34
Study 3581712 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 weeks' anticoagulation with heparin and warfarin
Number of subjects: 100
Study 3581712 — intervention group
Group type: COMPARATOR
Intervention: 6 weeks' anticoagulation with heparin and warfarin
Number of subjects: 100
Study 29446041 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnifying endoscopy with narrow band imaging (ME‐NBI)
Number of subjects: 24
Study 27187773 — intervention group
Group type: EXPERIMENTAL
Intervention: Advanced cookstove intervention
Number of subjects: 176
Study 27187773 — intervention group
Group type: EXPERIMENTAL
Intervention: IMCI pneumonia knowledge test
Number of subjects: 176
Study 27187773 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical evaluation checklist
Number of subjects: 176
Study 27187773 — intervention group
Group type: EXPERIMENTAL
Intervention: Key equipment checklist
Number of subjects: 176
Study 25714132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower systolic BP
Number of subjects: 220
Study 25714132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower diastolic BP
Number of subjects: 220
Study 25714132 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower mean arterial pressure (MAP)
Number of subjects: 220
Study 25714132 — intervention group
Group type: COMPARATOR
Intervention: Cortical gray matter or white matter volume
Number of subjects: 220
Study 23477657 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump CABG
Number of subjects: 2539
Study 23477657 — intervention group
Group type: COMPARATOR
Intervention: On-pump CABG
Number of subjects: 2539
Study 21169038 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany
Number of subjects: 36
Study 21169038 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilon/Epiphany SE
Number of subjects: 36
Study 21169038 — intervention group
Group type: COMPARATOR
Intervention: gutta‐percha/AH Plus
Number of subjects: 36
Study 18604331 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (accumulated dose of 400 mg)
Number of subjects: 38
Study 18604331 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam (accumulated dose of 15 mg)
Number of subjects: 38
Study 16311277 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium 40 mg kg(‐1) bolus followed by magnesium 10 mg kg(‐1) h(‐1) infusion
Number of subjects: 80
Study 16311277 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium 40 mg kg(‐1) bolus followed by magnesium 20 mg kg(‐1) h(‐1) infusion
Number of subjects: 80
Study 16311277 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 80
Study 12848834 — intervention group
Group type: EXPERIMENTAL
Intervention: LHWO+ME (Lay Health Worker Outreach + Media Education)
Number of subjects: 400
Study 12848834 — intervention group
Group type: COMPARATOR
Intervention: ME (Media Education)
Number of subjects: 400
Study 10910846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.02 mg/kg nicardipine
Number of subjects: 45
Study 10910846 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg diltiazem
Number of subjects: 45
Study 10910846 — intervention group
Group type: COMPARATOR
Intervention: saline (control)
Number of subjects: 45
Study 8721266 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiation field size: 5 x 5 cm (Group A)
Number of subjects: 273
Study 8721266 — intervention group
Group type: COMPARATOR
Intervention: Radiation field size: 6 x 6 cm (Group B)
Number of subjects: 273
Study 1411867 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 12
Study 1411867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3940258 — intervention group
Group type: EXPERIMENTAL
Intervention: Loperamide
Number of subjects: 24
Study 3940258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidamidine 12 mg
Number of subjects: 24
Study 3940258 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidamidine 18 mg
Number of subjects: 24
Study 3940258 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 31314598 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens 1 (radial refractive gradient design, nominal add power 2.00D)
Number of subjects: 30
Study 31314598 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens 2 (center-near design, nominal add power 1.50D)
Number of subjects: 30
Study 31314598 — intervention group
Group type: EXPERIMENTAL
Intervention: Lens 3 (center-near design, nominal add power 2.00D)
Number of subjects: 30
Study 31314598 — intervention group
Group type: COMPARATOR
Intervention: Monofocal control lens
Number of subjects: 30
Study 30355119 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracranial ICA patent at day 1
Number of subjects: 83
Study 30355119 — intervention group
Group type: EXPERIMENTAL
Intervention: Successful recanalization (modified Thrombolysis in Cerebral Infarction, 2b/3)
Number of subjects: 83
Study 30355119 — intervention group
Group type: COMPARATOR
Intervention: Prior intravenous thrombolysis
Number of subjects: 83
Study 30355119 — intervention group
Group type: COMPARATOR
Intervention: Cervical revascularization procedure (balloon angioplasty or stenting)
Number of subjects: 83
Study 27253458 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-week educational course and reinforcements every 4 months for one year
Number of subjects: 137
Study 27253458 — intervention group
Group type: COMPARATOR
Intervention: Control group (no structured diabetes mellitus education)
Number of subjects: 137
Study 24555502 — intervention group
Group type: EXPERIMENTAL
Intervention: Home visiting nurse intervention (HVN)
Number of subjects: 499
Study 24555502 — intervention group
Group type: COMPARATOR
Intervention: Care as usual
Number of subjects: 499
Study 22219343 — intervention group
Group type: EXPERIMENTAL
Intervention: I.V. acetazolamide (ACZ) 10 mg kg⁻¹
Number of subjects: 12
Study 19424889 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth intervention (Camperdown Program)
Number of subjects: 40
Study 19424889 — intervention group
Group type: COMPARATOR
Intervention: Face-to-face intervention (Camperdown Program)
Number of subjects: 40
Study 18383657 — intervention group
Group type: EXPERIMENTAL
Intervention: Sucking ice during chemotherapy
Number of subjects: 200
Study 18383657 — intervention group
Group type: COMPARATOR
Intervention: Other treatments (not specified)
Number of subjects: 200
Study 18383657 — intervention group
Group type: COMPARATOR
Intervention: Analgesics (especially morphine)
Number of subjects: 200
Study 18383657 — intervention group
Group type: COMPARATOR
Intervention: Local anaesthetics
Number of subjects: 200
Study 15928258 — intervention group
Group type: EXPERIMENTAL
Intervention: Black coffee
Number of subjects: 40
Study 15928258 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee with nondairy creamer and sugar
Number of subjects: 40
Study 15928258 — intervention group
Group type: COMPARATOR
Intervention: Control (no coffee)
Number of subjects: 40
Study 12753443 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block with bupivacaine 0.22% 4 mg.kg‐1 (1.8 ml.kg‐1) and morphine 150 microg x kg‐1
Number of subjects: 30
Study 12753443 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia with fentanyl 25 microg x kg‐1
Number of subjects: 30
Study 12753443 — intervention group
Group type: COMPARATOR
Intervention: General anaesthesia
Number of subjects: 30
Study 12753443 — intervention group
Group type: EXPERIMENTAL
Intervention: Caudal block
Number of subjects: 30
Study 10325255 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (stopped at menses) in IVF-SL group
Number of subjects: 99
Study 10325255 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (continued throughout stimulation) in IVF-LL group
Number of subjects: 99
Study 10325255 — intervention group
Group type: EXPERIMENTAL
Intervention: Leuprolide acetate (continued throughout stimulation) in oocyte donors
Number of subjects: 99
Study 8565196 — intervention group
Group type: EXPERIMENTAL
Intervention: MethaSite (0.1% fluorometholone gel‐forming suspension)
Number of subjects: 105
Study 8565196 — intervention group
Group type: COMPARATOR
Intervention: FML S.O.P. (0.1% fluorometholone ointment)
Number of subjects: 105
Study 2016630 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic vancomycin 15 mg/kg every 12 hours from day -2 until resolution of neutropenia or until the first episode of fever
Number of subjects: 60
Study 2016630 — intervention group
Group type: COMPARATOR
Intervention: Control group (no vancomycin)
Number of subjects: 60
Study 2016630 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic vancomycin
Number of subjects: 60
Study 7224109 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram terbutaline injected intradermally (i.d.)
Number of subjects: 15
Study 7224109 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 microgram terbutaline injected i.d. followed by allergen challenge
Number of subjects: 15
Study 7224109 — intervention group
Group type: EXPERIMENTAL
Intervention: Rechallenge with the same allergen or a dissimilar challenging agent
Number of subjects: 15
Study 7224109 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin challenged with allergen in the presence of terbutaline
Number of subjects: 15
Study 7224109 — intervention group
Group type: COMPARATOR
Intervention: Rechallenge with an unrelated allergen or compound 48/80
Number of subjects: 15
Study 31067545 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesalazine (4 g/day)
Number of subjects: 4
Study 28687413 — intervention group
Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg three times per week for 48 weeks
Number of subjects: 420
Study 28687413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study 25502348 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Illusion (VI)
Number of subjects: 24
Study 25502348 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous Electrical Nerve Stimulation (TENS)
Number of subjects: 24
Study 23866815 — intervention group
Group type: EXPERIMENTAL
Intervention: Ongoing theory-based educational intervention with dedicated liaison practitioners to train clinical staff
Number of subjects: 0
Study 23866815 — intervention group
Group type: COMPARATOR
Intervention: Postal information about the local early intervention in psychosis service
Number of subjects: 0
Study 20922542 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic surgery
Number of subjects: 40
Study 20922542 — intervention group
Group type: COMPARATOR
Intervention: Open surgery
Number of subjects: 40
Study 19507456 — intervention group
Group type: EXPERIMENTAL
Intervention: e/Tablet electronic format
Number of subjects: 56
Study 19507456 — intervention group
Group type: COMPARATOR
Intervention: paper version
Number of subjects: 56
Study 16550416 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychiatric day‐hospital treatment
Number of subjects: 202
Study 16550416 — intervention group
Group type: COMPARATOR
Intervention: Inpatient treatment
Number of subjects: 202
Study 15191512 — intervention group
Group type: EXPERIMENTAL
Intervention: Transarterial chemoembolization (TACE)
Number of subjects: 310